Brainstorm Cell Therapeutics Inc. (BCLI)
NASDAQ: BCLI · Real-Time Price · USD
1.730
-0.070 (-3.89%)
Feb 21, 2025, 4:00 PM EST - Market closed
BCLI Employees
Brainstorm Cell Therapeutics had 29 employees as of December 31, 2023. The number of employees decreased by 14 or -32.56% compared to the previous year.
Employees
29
Change (1Y)
-14
Growth (1Y)
-32.56%
Revenue / Employee
n/a
Profits / Employee
-$490,621
Market Cap
9.87M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 72,000 |
BCLI News
- 7 weeks ago - BrainStorm Issues 2024 Letter to Shareholders - PRNewsWire
- 2 months ago - BrainStorm Cell Therapeutics to Host Investor Call and Provide a Corporate Update - PRNewsWire
- 2 months ago - BrainStorm Strengthens Exosome Patent Portfolio: Receives Notice of Allowance for U.S. Patent Covering Its Platform Technology - PRNewsWire
- 2 months ago - BrainStorm Cell Therapeutics to Host KOL Webinar on Current Developments in the Treatment of Amyotrophic Lateral Sclerosis (ALS) on December 11, 2024 - PRNewsWire
- 3 months ago - BrainStorm Cell Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update - PRNewsWire
- 3 months ago - BrainStorm Cell Therapeutics and Pluri Partner to Support NurOwn® Phase 3b Trial Manufacturing - PRNewsWire
- 4 months ago - BrainStorm Cell Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement - PRNewsWire
- 4 months ago - BrainStorm Cell Therapeutics Presented Positive Survival Data from NurOwn® Expanded Access Program at 2024 Annual NEALS Meeting - PRNewsWire